Literature DB >> 14706969

International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections.

David L Paterson1, Wen-Chien Ko, Anne Von Gottberg, Sunita Mohapatra, Jose Maria Casellas, Herman Goossens, Lutfiye Mulazimoglu, Gordon Trenholme, Keith P Klugman, Robert A Bonomo, Louis B Rice, Marilyn M Wagener, Joseph G McCormack, Victor L Yu.   

Abstract

BACKGROUND: Commonly encountered nosocomially acquired gram-negative bacteria, especially Klebsiella pneumoniae, produce extended-spectrum beta-lactamases (ESBLs) as an antibiotic resistance mechanism.
OBJECTIVE: To determine whether microbiology laboratories should report the presence of ESBLs and to establish the infection-control implications of ESBL-producing organisms.
DESIGN: Prospective observational study.
SETTING: 12 hospitals in South Africa, Taiwan, Australia, Argentina, the United States, Belgium, and Turkey. PATIENTS: 440 patients with 455 consecutive episodes of K. pneumoniae bacteremia between 1 January 1996 and 31 December 1997; of these, 253 episodes were nosocomially acquired. MEASUREMENTS: The K. pneumoniae isolates were examined for the presence of ESBLs. Pulsed-field gel electrophoresis was used to analyze the molecular epidemiology of nosocomial bacteremia with ESBL-producing K. pneumoniae.
RESULTS: Overall, 30.8% (78 of 253) episodes of nosocomial bacteremia and 43.5% (30 of 69) episodes acquired in intensive care units were due to ESBL-producing organisms. After adjustment for potentially confounding variables, previous administration of beta-lactam antibiotics containing an oxyimino group (cefuroxime, cefotaxime, ceftriaxone, ceftazidime, or aztreonam) was associated with bacteremia due to ESBL-producing strains (risk ratio, 3.9 [95% CI, 1.1 to 13.8]). In 7 of 10 hospitals with more than 1 ESBL-producing isolate, multiple strains with the same genotypic pattern were observed, indicating patient-to-patient spread of the organism.
CONCLUSIONS: Production of ESBLs by Klebsiella pneumoniae is a widespread nosocomial problem. Appropriate infection control and antibiotic management strategies are needed to stem the spread of this emerging form of resistance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14706969     DOI: 10.7326/0003-4819-140-1-200401060-00008

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  170 in total

1.  Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis.

Authors:  Pilar Retamar; María M Portillo; María Dolores López-Prieto; Fernando Rodríguez-López; Marina de Cueto; María V García; María J Gómez; Alfonso Del Arco; Angel Muñoz; Antonio Sánchez-Porto; Manuel Torres-Tortosa; Andrés Martín-Aspas; Ascensión Arroyo; Carolina García-Figueras; Federico Acosta; Juan E Corzo; Laura León-Ruiz; Trinidad Escobar-Lara; Jesús Rodríguez-Baño
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

2.  Impact of penicillin nonsusceptibility on clinical outcomes of patients with nonmeningeal Streptococcus pneumoniae bacteremia in the era of the 2008 clinical and laboratory standards institute penicillin breakpoints.

Authors:  Seong-Ho Choi; Jin-Won Chung; Heungsup Sung; Mi-Na Kim; Sung-Han Kim; Sang-Oh Lee; Yang Soo Kim; Jun Hee Woo; Sang-Ho Choi
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

3.  Clinical characteristics of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in the era of CTX-M-type and KPC-type β-lactamases.

Authors:  Z A Qureshi; D L Paterson; A Y Peleg; J M Adams-Haduch; K A Shutt; D L Pakstis; E Sordillo; B Polsky; G Sandkovsky; M K Bhussar; Y Doi
Journal:  Clin Microbiol Infect       Date:  2011-09-26       Impact factor: 8.067

4.  Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods.

Authors:  Brian C Nelson; Daniel P Eiras; Angela Gomez-Simmonds; Angela S Loo; Michael J Satlin; Stephen G Jenkins; Susan Whittier; David P Calfee; E Yoko Furuya; Christine J Kubin
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

Review 5.  Bacterial Infection in Patients with Cirrhosis: Don't Get Bugged to Death.

Authors:  Mary D Cannon; Paul Martin; Andres F Carrion
Journal:  Dig Dis Sci       Date:  2020-01       Impact factor: 3.199

6.  agr functionality affects clinical outcomes in patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia.

Authors:  C K Kang; Y K Kim; S-I Jung; W B Park; K-H Song; K-H Park; P G Choe; H-C Jang; S Lee; Y-S Kim; Y G Kwak; K T Kwon; S Kiem; C-J Kim; E S Kim; H B Kim
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-06-21       Impact factor: 3.267

7.  Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility.

Authors:  Oren Zimhony; Inna Chmelnitsky; Rita Bardenstein; Sorel Goland; Orly Hammer Muntz; Shiri Navon Venezia; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

8.  Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Escherichia coli in Patients with Hematologic Malignancy.

Authors:  Grace E Benanti; Anne Rain T Brown; Terri Lynn Shigle; Jeffrey J Tarrand; Micah M Bhatti; Patrick M McDaneld; Samuel A Shelburne; Samuel L Aitken
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

9.  Risk Factors, Outcomes, and Mechanisms of Tigecycline-Nonsusceptible Klebsiella pneumoniae Bacteremia.

Authors:  Chih-Han Juan; Yi-Wei Huang; Yi-Tsung Lin; Tsuey-Ching Yang; Fu-Der Wang
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

10.  Strategic design of an effective beta-lactamase inhibitor: LN-1-255, a 6-alkylidene-2'-substituted penicillin sulfone.

Authors:  Priyaranjan Pattanaik; Christopher R Bethel; Andrea M Hujer; Kristine M Hujer; Anne M Distler; Magdalena Taracila; Vernon E Anderson; Thomas R Fritsche; Ronald N Jones; Sundar Ram Reddy Pagadala; Focco van den Akker; John D Buynak; Robert A Bonomo
Journal:  J Biol Chem       Date:  2008-10-27       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.